Medication Optimisation for Reducing Events in a Private Practice Setting (MORE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00653653|
Recruitment Status : Unknown
Verified April 2009 by Awenydd GmbH.
Recruitment status was: Active, not recruiting
First Posted : April 7, 2008
Last Update Posted : April 8, 2009
Using a prospective study design of two three month periods (before and after genotyping) in which the patients will self-monitor their health status and possible medical events it is hypothesized that it will be shown that patients having their medication altered to fit their genetic status and/or having their medication altered because of inherent interaction potential will have less recordable events after genotyping and medical analysis than before.
It is well known that ADRs (recordable adverse events to medication) are responsible for a large number of deaths and hospitalizations. Furthermore it is well recorded that genotyping of individual cytochrome P450 enzymes (2D6, 2C9, 2C19, among others) is directly related to a metabolic phenotype - fast metabolisers, slow metabolisers, intermediate and normal metabolisers. These differing phenotypes have altered metabolism of many medications and in a number of retrospective clinical trails it has been shown that ADRs and effect can be reduced/bettered through genotyping and alteration of medication.
|Condition or disease|
|Pharmacogenetic Analysis to Reduce Events.|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.|
|Study Start Date :||August 2008|
|Estimated Primary Completion Date :||June 2009|
|Estimated Study Completion Date :||October 2009|
Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
- Reduction of reported events in the time frame. [ Time Frame: 3 months ]
- Reduction of total costs associated per patient in the time frame. [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653653
|Köln, NRW, Germany, 50829|
|Study Director:||Lee S Griffith, Ph.D.||Awenydd GmbH|
|Principal Investigator:||André Gessner, MD Ph.D.||University of Erlangen-Nürnberg|